Clinical Trials Logo
  1. Home
  2. Hyperparathyroidism, Secondary
  3. NCT04126954

Study on the Use of Cinacalcet in Phosphocalcic Context. — CALCI-CINA  

Hyperparathyroidism, Secondary Clinical Trial

Official title:
Multicentric Retrospective Study on the Use of Cinacalcet in an Off-label Phosphocalcic Context

Clinical Trial Summary

Currently, the indications used for MA (Marketing Authorization) Cinacalcet in France are hyperparathyroidism (hyperPTH) in adults, whether primary (for patients in whom parathyroidectomy is theoretically indicated but in whom it is contraindicated or not is not clinically appropriate) or secondary to a chronic kidney disease, and parathyroid carcinomas.

In pediatric patients, data on its use are restricted due to its recent marketing authorization (2017) and limited to dialysis patients suffering from secondary hyperPTH.

Nevertheless, some patients with phosphocalcic pathologies without renal insufficiency must be treated off-label by cinacalcet in the presence of severe hyperPTH, without any other chronic treatment available to date.

The objective of this study is therefore to evaluate the use in France of cinacalcet in phosphocalcic pathologies without renal insufficiency, in order to obtain efficacy and safety data in order to improve our knowledge on the management of these orphan diseases.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04126954
Study type Observational
Source Hospices Civils de Lyon
Contact Justine BACCHETTA, MD
Phone 4 27 85 61 30
Email justine.bacchetta@chu-lyon.fr
Status Not yet recruiting
Phase
Start date January 2020
Completion date December 2023
View Details
See also
  Status Clinical Trial Phase
Completed NCT01134562 - Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism Phase 1
Completed NCT02523209 - Analysis of Bone Microarchitecture With HR-pQCT of Patients With Chronic Kidney Disease (CKD) Candidates for Renal Transplantation N/A
Completed NCT01922843 - A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis Phase 2
Completed NCT01651000 - Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency Phase 3
Completed NCT00528788 - How Vitamin D Analogues Affect Endothelial Cells in Patients on Dialysis Phase 4
Completed NCT01181531 - Compare the Efficacy of Cinacalcet vs Traditional Vitamin D for Secondary Hyperparathyroidism (SHPT) Among Subjects Undergoing Hemodialysis Phase 4
Completed NCT05382988 - Sodium Zirconium Cyclosilicate Lowers Hyperkalemia After Parathyroidectomy Phase 3
Completed NCT02056730 - The Study of Efficacy and Safety of REGPARA Drug in Dialysis Patients Have High Blood Levels of Parathyroid Phase 4
Completed NCT01704079 - Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency Phase 3
Completed NCT00397475 - Evaluation of Colecalciferol Substitution in Dialysis Patients N/A
Withdrawn NCT03063190 - Cholecalciferol Supplementation in Restless Leg Syndrome in Patients With Chronic Kidney Disease Phase 4
Completed NCT02102204 - Extension Study of Etelcalcetide for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on Hemodialysis Phase 3
Recruiting NCT02273570 - Optimal Anemia Treatment in End Stage Renal Disease (ERSD) N/A
Completed NCT01785849 - Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease on Hemodialysis Phase 3
Completed NCT01788046 - Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis Phase 3
Terminated NCT01277510 - Pediatric Chronic Kidney Disease Safety and Efficacy Phase 3
Terminated NCT01439867 - Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism Phase 2
Completed NCT01134549 - Safety, Tolerability and Pharmacokinetics of KAI-4169 in Healthy Male Volunteers Phase 1
Completed NCT01785875 - Extension Study of Etelcalcetide in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis Phase 3
Active, not recruiting NCT02464072 - Subtotal Parathyroidectomy or Total Parathyroidectomy With Autograft in Chronic Kidney Disease Patients Under Dialysis N/A